Dual‑targeting nanomicelles with CD133 and CD44 
aptamers for enhanced delivery of gefitinib to 
two populations of lung cancer‑initiating cells

Huang,Xiaolong; Wan,Jun; Leng,Dewen; Zhang,Yingying; Yang,Shuo

doi:10.3892/etm.2019.8220

Dual‑targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer‑initiating cells

Authors:
- Xiaolong Huang
- Jun Wan
- Dewen Leng
- Yingying Zhang
- Shuo Yang
View Affiliations

Affiliations: Department of Respiratory Medicine, Wuhan No. 1 Hospital, Wuhan, Hubei 430022, P.R. China, Department of Critical Care Medicine, Wuhan No. 1 Hospital, Wuhan, Hubei 430022, P.R. China, Department of Pharmacy, Naval Medical University, Shanghai 200433, P.R. China
Published online on: November 19, 2019 https://doi.org/10.3892/etm.2019.8220
Pages: 192-204
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is an aggressive type of cancer that is associated with a high mortality rate. Lung cancer‑initiating cells are populations of self‑renewing cancer cells with pluripotent differentiation ability. Cancers typically originate from multiple phenotypically distinct cancer‑initiating cells. CD133 and CD44 are specific markers that maybe used to distinguish lung cancer‑initiating cells. The ability to target a variety of subsets of cancer‑initiating cells instead of targeting only one population of cancer initiating‑cells has the potential to increase the cancer therapeutic efficacy. In the present study, CD133 and CD44 aptamer‑conjugated nanomicelles loaded with gefitinib (CD133/CD44‑NM‑Gef) were developed to target CD133+ and CD44+ lung cancer‑initiating cells. The therapeutic efficacy of CD133/CD44‑NM‑Gef against lung cancer‑initiating cells was assessed by evaluating cell proliferation, tumorsphere formation and detection of CD44+ and CD133+ cells using flow cytometry. The results indicated that CD133/CD44‑NM‑Gef targeted CD133+ and CD44+ lung cancer‑initiating cells and exhibited greater therapeutic efficacy against lung cancer‑initiating cells than single‑target and non‑targeted nanomicelles, suggesting that CD133/CD44‑NM‑Gef represents a promising treatment for lung cancer by specifically targeting lung cancer‑initiating cells. To the best of our knowledge, the present study was the first to report on drug delivery via nanomedicines targeted to multiple populations of cancer‑initiating cells using aptamers. As cancer is typically derived from phenotypically distinct cancer‑initiating cells, the nanomicelle‑based multiple targeting strategy provided is promising for targeting multiple subsets of cancer‑initiating cell within a tumor.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De Maria R: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
4	Kim JJ and Tannock IF: Repopulation of cancer cells during therapy: An important cause of treatment failure. Nat Rev Cancer. 5:516–525. 2005. View Article : Google Scholar : PubMed/NCBI
5	Zakaria N, Satar NA, Abu Halim NH, Ngalim SH, Yusoff NM, Lin J and Yahaya BH: Targeting lung cancer stem cells: Research and clinical impacts. Front Oncol. 7:802017. View Article : Google Scholar : PubMed/NCBI
6	Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al: Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA. 106:16281–16286. 2009. View Article : Google Scholar : PubMed/NCBI
7	Huang X, Huang J, Leng D, Yang S, Yao Q, Sun J and Hu J: Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells. World J Surg Oncol. 15:1672017. View Article : Google Scholar : PubMed/NCBI
8	Meyer MJ, Fleming JM, Lin AF, Hussnain SA, Ginsburg E and Vonderhaar BK: CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 70:4624–4633. 2010. View Article : Google Scholar : PubMed/NCBI
9	Stewart JM, Shaw PA, Gedye C, Bernardini MQ, Neel BG and Ailles LE: Phenotypic heterogeneity and instability of human ovarian tumor-initiating cells. Proc Natl Acad Sci USA. 108:6468–6473. 2011. View Article : Google Scholar : PubMed/NCBI
10	Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
11	Jain RK and Stylianopoulos T: Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 7:653–664. 2010. View Article : Google Scholar : PubMed/NCBI
12	Li W, Li J, Gao J, Li B, Xia Y, Meng Y, Yu Y, Chen H, Dai J, Wang H, et al: The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials. 32:3832–3844. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li W, Zhao H, Qian W, Li H, Zhang L, Ye Z, Zhang G, Xia M, Li J, Gao J, et al: Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials. 33:5349–5362. 2012. View Article : Google Scholar : PubMed/NCBI
14	Ashok B, Arleth L, Hjelm RP, Rubinstein I and Onyüksel H: In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: Effects of PEG chain length and PC incorporation. J Pharm Sci. 93:2476–2487. 2004. View Article : Google Scholar : PubMed/NCBI
15	Zhao BJ, Ke XY, Huang Y, Chen XM, Zhao X, Zhao BX, Lu WL, Lou JN, Zhang X and Zhang Q: The antiangiogenic efficacy of NGR-modified PEG-DSPE micelles containing paclitaxel (NGR-M-PTX) for the treatment of glioma in rats. J Drug Target. 19:382–390. 2011. View Article : Google Scholar : PubMed/NCBI
16	Mao X, Liu J, Gong Z, Zhang H, Lu Y, Zou H, Yu Y, Chen Y, Sun Z, Li W, et al: iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Nanomedicine (Lond). 10:2677–2695. 2015. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C (T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Cushing BL, Kolesnichenko VL and O'Connor CJ: Recent advances in the liquid-phase syntheses of inorganic nanoparticles. Chem Rev. 104:3893–3946. 2004. View Article : Google Scholar : PubMed/NCBI
19	Gao J, Ochyl LJ, Yang E and Moon JJ: Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting degradation of antigens. J Nanomedicine. 12:1251–1264. 2017.
20	Gao J, Chen H, Song H, Su X, Niu F, Li W, Li B, Dai J, Wang H and Guo Y: Antibody-targeted immunoliposomes for cancer treatment. Mini Rev Med Chem. 13:2026–2035. 2013. View Article : Google Scholar : PubMed/NCBI
21	Passiglia F, Listì A, Castiglia M, Perez A, Rizzo S, Bazan V and Russo A: EGFR inhibition in NSCLC: New findings and opened questions? Crit Rev Oncol Hematol. 112:126–135. 2017. View Article : Google Scholar : PubMed/NCBI
22	Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR and Adamis AP: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 5:123–132. 2006. View Article : Google Scholar : PubMed/NCBI
23	Gao J, Li W, Guo Y and Feng SS: Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine (Lond). 11:3261–3282. 2016. View Article : Google Scholar : PubMed/NCBI
24	Gong Z, Chen D, Xie F, Liu J, Zhang H, Zou H, Yu Y, Chen Y, Sun Z, Wang X, et al: Codelivery of salinomycin and doxorubicin using nanoliposomes for targeting both liver cancer cells and cancer stem cells. Nanomedicine (Lond). 11:2565–2579. 2016. View Article : Google Scholar : PubMed/NCBI
25	Xie F, Zhang S, Liu J, Gong Z, Yang K, Zhang H, Lu Y, Zou H, Yu Y, Chen Y, et al: Codelivery of salinomycin and chloroquine by liposomes enables synergistic antitumor activity in vitro. Nanomedicine (Lond). 11:1831–1846. 2016. View Article : Google Scholar : PubMed/NCBI
26	Wang M, Xie F, Wen X, Chen H, Zhang H, Liu J, Zhang H, Zou H, Yu Y, Chen Y, et al: Therapeutic PEG-ceramide nanomicelles synergize with salinomycin to target both liver cancer cells and cancer stem cells. Nanomedicine (Lond). 12:1025–1042. 2017. View Article : Google Scholar : PubMed/NCBI
27	Naujokat C and Steinhart R: Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012:9506582012. View Article : Google Scholar : PubMed/NCBI
28	Gao J, Feng SS and Guo Y: Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond). 5:1141–1145. 2010. View Article : Google Scholar : PubMed/NCBI
29	Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R and Rochlitz C: Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: A phase 1 dose-escalation study. Lancet Oncol. 13:1234–1241. 2012. View Article : Google Scholar : PubMed/NCBI
30	Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, et al: HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer. 16:3522016. View Article : Google Scholar : PubMed/NCBI